Pharmaxis - Articles and news items

Successful Phase 1 results for cardiometabolic disease drug PXS-4728A

Industry news / 22 September 2015 / Victoria White

PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress…

HM61713

Boehringer Ingelheim acquires Pharmaxis’ investigational drug PXS4728A

Industry news / 18 May 2015 / Victoria White

Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+